Oncolytics Biotech Inc ONCY

Roche CD47 antibody start-up gives up-lays off all employees

[Noteable]

Thanks to Dude1234 on Stocktwits for providing the heads-up

https://endpts.com/scoop-roche-backed-startup-gives-up-on-cd47-as-ceo-most-employees-leave/

[Noteable]

This development involving Arch Oncology places further pressure on Roche to do a deal with ONCY in an effort to bolster and expand the products and indications supporting Roche's existing product pipeline that is focused on their immune checkpoint inhibitor Tecentriq (atezolizumab).

[Noteable]

Ka-ching, Ka-ching. ONCY's negotiation power and acquisition value has just gone up.

[westcoast1000]

If the boost to Tecentriq given by pela in the panc results has carried over to the BC results (which they have not released yet AFAIK, then I cannot imagine Roche not attempting a purchase of ONCY> Tencentriq is something like 12% of their total pharma revenues, and combined with pela it both expands the scope of patients that can be treated, and increases the effects, it also allows the use

[Noteable]

In April 2021 ONCY's AWARE-1 demonstrated that " Pelareorep and (Roche's) atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients" Treatment with pelareorep alone or in combination with atezolizumab increased tumor PD-L1 expression and led to the conversion of PD-L1 negative tumors into PD-L1 positive tumors "These exciting

[fox7mf]

I agree WC. We're in need of some news, and Roche seems like the most likely candidate to make a move on ONCY. Will they? We might have to wait until ESMO, or even early next to find out.

[13X2413]

I think it's time to stop fantasizing about buyouts. Focus should be on news from the company on the effectiveness of what they have. Will there be anything new coming? If not, we will just try to stay afloat    

[westcoast1000]

The results that were announced last fall and then this June are more than enough to keep us afloat. I really do not understand your comment. The effectiveness of what we have has been demonstrated clearly.

[Angler101]

Hey Fox!....cmon man!......what’s going on....you ok?......most of us are supposed to be on the same side here!......why you pickin on Notable?......I know you’re getting anxious...so is everybody else....but our time is coming....and I believe it’s coming sooner than you think.....but pickin on Notable ain’t gonna make it come any sooner, mate!.....with all due respect, Fox, can’t you see that a

[fox7mf]

Why don't you reread that whole thread to figure out my reference to Bay Bridge was only in support of Oncy, simply suggesting that we should presently have a market cap of $2.5b + and not what we actually have. It was Noteable who decided to start throwing the "fud" insult around. In any event, who cares anymore...misunderstandings are just a waste of energy. 

[Noteable]

Roche's anti-TIGIT drug tiragolumab also has not done very well - placing Roche's continued hope on their immune checkpoint inhibitor Tecentriq. https://www.reuters.com/business/healthcare-pharmaceuticals/roches-late-stage-trial-two-lung-cancer-drugs-fails-2022-05-11/

[Noteable]

September 25, 2023 - Abbvie is another Big Pharma company who've axed its CD47 candidate. https://www.fiercebiotech.com/biotech/abbvie-axes-i-mab-pact-exit-fast-thinning-race-cd47-space

[Noteable]

AbbVie wrote to Chinese based company I-Mab to terminate the license and collaboration agreement last week.  In a growing pessimistic sentiment towards China, Abbvie is the latest Big Pharma to cut ties with Chinese base companies.

[Noteable]

Repost from January 13, 2023  hanks to Dude1234 on Stocktwits for providing the heads-up https://endpts.com/scoop-roche-backed-startup-gives-up-on-cd47-as-ceo-most-employees-leave/ Along with Roche's CD47 acquisition, Roche's anti-TIGIT drug tiragolumab also has not done very well - placing Roche's continued hope on their immune checkpoint inhibitor Tecentriq.

[Noteable]

Prior to this and other similar news Pfizer acquired pre-clinical CD47 blockade company Trillium Therapeutics for U$2.3 Billion which re-emphasizes the point that a company's stock price does not correlate to a company's ultimate merger and acquistion (M&A) price.

[Noteable]

July 24, 2023 - Gilead drops CD47 candidate in Phase 3 study Gilead as discontinued Phase III ENHANCE study of its investigational anti-CD47 antibody magrolimab for the treatment of patients with higher-risk myelodysplastic syndromes, the company announced Friday.  In January 2022, the FDA slapped a partial clinical hold on all trials evaluating magrolimab in combination with

[Noteable]

In March 2020 Gilead acquired the CD47 company Forty Seven for US$ 4.9 Billion. https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion

[Noteable]

As previously posted in January 2023, " The development of CD47 antibodies is primarily hampered by their on-target binding to red blood cells (RBCs). Therefore, various CD47 antibodies in their clinical development are found to be susceptible to severe anemia and other hematologic side effects. As a result, many CD47 antibody programs have been either terminated in early clinical trials

[fox7mf]

Great find Noteable. I always looked towards the Forty Seven acquisition amount as appropriate for Oncy before PDAC & CRC proved out, when we were just the mBC indication. Now Gilead would have to spend in & around triple that $4.9b to get Oncy.

[m00nsh0ts]

These BP keep pissing away their treasury, let's hope there's enough left for a handsome buyout of oncy.

[askretka]

I did read somewhere that one company was trying to get a CD47 ab to the target by attaching it to an Oncolytic Virus.  Don't know what Virus they were using though. Since OVs only infect cancer cells it sremed like a good strategy.   CD47 is on a lot of our cells including RBC and platelets so people with anemia, which is a lot of cancer patients would be at risk, without

[Noteable]

ONCY's OV pelareorep works to neutralize CD47 https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=34790799

[Noteable]

As posted in June 2022, .." the relationship between the CD47 "don't eat me" signal / CD47 antibodies / and the oncolytic virus like pelareorep work to neutralize CD47 on tumor cells and promotes phagocytosis, thus complementing anti-CD-47 agents such as the one that Pfizer acquired through the Trillium acquisition for US$ 2.26 Billion." https://www.ncbi.nlm.nih.gov/pmc

[askretka]

Good to know. Haven't done  lot of reading  on CD47 really.  Thanks. Cheers!!!!

[Noteable]

Aug 21, 2023 - Gilead Sciences revealed its CD47 molecule has been placed under a partial clinical hold by the FDA for its phase 3 acute myeloid leukemia (AML) studies. The news comes a month to the day after Gilead revealed it had canned studies in MDS for the CD47 asset, which was acquired along with Forty Seven for $4.9 billion. Gilead shut the late-stage study down for futility

[Noteable]

Septembe 27, 2023 - Gilead Sciences’ anti-CD47 antibody has again disappointed in a Phase III blood cancer trial. The biopharma announced the decision to discontinue another late-stage study of magrolimab Tuesday.   This is the second Phase III study ended for the investigational treatment. In July 2023, Gilead put a stop to its ENHANCE study of magrolimab for the high

[Noteable]

February 16, 2024 - Gilead Sciences  on Thursday suspended patient enrollment in its clinical trials studying the investigational anti-CD47 antibody magrolimab in solid tumors. Magrolimab was picked up by Gilead in 2020 with a $4.9 billion buy of Forty Seven, an immuno-oncology biotech that spun out of Stanford.  https://www.biospace.com/article/gilead-suspends

[Noteable]

October 05, 2023 - US clinical-stage immuno-oncology company ALX Oncology Holdings (Nasdaq: ALXO) saw its shares rocket 56% to $7.51 yesterday, as it announced positive clinical results for its lead asset after a previous disappointment.  ALX announced positive prespecified interim Phase II data from its ASPEN-06 clinical trial, a randomized multi-center international study evaluating

[Noteable]

ALX Oncology Holdings (Nasdaq: ALXO) is a mid-stage Phase II clinical development company trading at around US$7.00 p/s https://alxoncology.com/pipeline/

[Noteable]

April 26, 2024 - Gilead quietly provided an update on [its CD47] program after the market closed Thursday, removing all solid tumor trials of the CD47 drug candidate from its pipeline as part of its first quarter results update (PDF). The antibody is now completely absent from Gilead’s pipeline.  The pipeline update marked a muted end to a molecule that was once central

[Noteable]

June 14, 2024 - Gilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective, but could potentially be harmful to patients with untreated high-risk myelodysplastic syndrome, according to new data from a phase 3 study presented at 2024’s European Hematology Association (EHA) meeting. Magrolimab showed worse performances compared with placebo

[canadafan]

Interesting post, regarding the phase 3 , after time delay results.presented by Noteable. My assumption his comparison to Gilead, is regarding the extreamly safe outcomes from ONC's Pelareorep? Some have used sarcasm in the past regarding Pela being safe & well tolerated. reality, THAT is a very important attribute of Pelareorep. Proven in over 1000 patients, various studies, Pela at worst

[Cblifeforms]

This has a BIG meaning for us

[Noteable]

Pfizer acquisition of Trillium Therapeutics CD47 for US$2.3 Billion can potentially see ONCYs pelareorep combined with Pfizers CD47, bispecifics, CD4/6 and PARP inhibitors along with the ADCs that will come from Pfizers upcoming acquisition of Seagen, as previously outlined.  [ Pfizers Elrexfio, and J&J/Janssens Tecvayli and Talvey are off-the-shelf drugs called

[Noteable]

** ONCY - The Most Undervalued Oncolytics Company On The Nasdaq **

[Noteable]

May 17, 2024 - An early data abstract on Shattuck Labs’ anti-CD-47 SL-172154, released yesterday at the upcoming European Hematology Association conference, has reported waning efficacy, a heart attack, and a death.

[Noteable]

Phase 1 early stage clinical development company Shattuck Labs Inc was trading at a May 2024 high of US$ 11.18

[Noteable]

In November 2021 Pfizer completed the acquisition of early stage Phase 1 anti-CD-47 company Trillium Therapeutics for US$ 2.26 Billion. https://aacrjournals.org/cancerdiscovery/article/11/11/2666/666437/Pfizer-Acquires-Trillium-Gains-Anti-CD47

[Noteable]

Shattuck last to axe CD47 program. https://www.fiercebiotech.com/biotech/shattuck-axes-cd47-program-over-weak-efficacy-data-lays-40-staff-and-loses-ono-deal